Taysha gene therapies, inc.TSHA.US Overview
TSHA Overall Performance
TSHA AI Analysis & Strategy
TSHA Recent Performance
3.23%
Taysha gene therapies, inc.
0.81%
Avg of Sector
-1.14%
S&P500
TSHA PowerScanner
TSHA Key Information
TSHA Valuation Metrics
TSHA Earnings Table
TSHA Profile
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.